AR063912A1 - Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. - Google Patents
Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.Info
- Publication number
- AR063912A1 AR063912A1 ARP070105204A ARP070105204A AR063912A1 AR 063912 A1 AR063912 A1 AR 063912A1 AR P070105204 A ARP070105204 A AR P070105204A AR P070105204 A ARP070105204 A AR P070105204A AR 063912 A1 AR063912 A1 AR 063912A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- formula
- represented
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
El compuesto de la presente es de utilidad como un fármaco para la prevención o el tratamiento de enfermedades circulatorias, enfermedades metabólicas y/o enfermedades del sistema nervioso central. Composiciones farmacéuticas que los comprenden. Reivindicación 1: Un compuesto caracterizado porque esta representado por la siguiente fórmula (1) en donde R1 es (1) un grupo oxo; (2) un grupo tioxo; (3) un grupo representado por la fórmula: =N-R en donde R es (i) un grupo alquilo C1-6 opcionalmente sustituido; (ii) un grupo cicloalquilo C3-6 opcionalmente sustituido; (iii) un grupo representado por la fórmula: -O-Ra en donde Ra es hidrógeno, un grupo alquilo C1-6 opcionalmente sustituido o un grupo cicloalquilo C3-6 opcionalmente sustituido; o (iv) un grupo representado por la fórmula: -N(Rb)-Rc en donde Rb y Rc son cada uno, de modo independiente, hidrógeno, un grupo alquilo C1-6 opcionalmente sustituido o un grupo cicloalquilo C3-6 opcionalmente sustituido, o Rb y Rc se unen entre si para formar, junto con el átomo de nitrógeno unido, un grupo heterocíclico opcionalmente sustituido que contiene nitrógeno; (4) un grupo representado por la fórmula: =N-CO-R' en donde R' es un grupo alquilo C1-6 opcionalmente sustituido o un grupo cíclico opcionalmente sustituido; (5) un grupo representado por la fórmula: =N-CO-OR' en donde R' es como se definió con anterioridad; o (6) un grupo representado por la fórmula: =N-SO2-R' en donde R' es como se definió con anterioridad; y un grupo representado por la fórmula (2); es fórmulas (3) en donde R2 es un grupo representado por la fórmula (4) en donde R6 es un grupo representado por la fórmula (5) en donde Z es O o S(O)n (n es un número entero de 0 a 2), e Y es un grupo alquileno C1-4 opcionalmente sustituido o un grupo representado por la fórmula: -O-W-, -W-O-, -N(Rd)-W- o -W-N(Rd)- en donde W es un enlace o un grupo alquileno C1-4 opcionalmente sustituido, y Rd es un grupo alquilo C1-6 opcionalmente sustituido o un grupo cicloalquilo C3-6 opcionalmente sustituido (el grupo bifenilo también está opcionalmente sustituido) R3 y R4 son cada uno, de modo independiente, (1) hidrógeno, (2) un grupo alquilo C1-6 opcionalmente sustituido, (3) un grupo cicloalquilo C3-6 opcionalmente sustituido, (4) un grupo alcoxi C1-6 opcionalmente sustituido, (5) un grupo cicloalquil C3-6-oxi opcionalmente sustituido, (6) un grupo alquil C1-6-amino opcionalmente sustituido, (7) un grupo dialquil C1-6-amino opcionalmente sustituido o (8) un grupo alquil C1-6-tio opcionalmente sustituido; y R5 es (1) hidrógeno, (2) un grupo alquilo C1-6 opcionalmente sustituido, (3) un grupo alquenilo C2-6 opcionalmente sustituido, (4) un grupo cíclico opcionalmente sustituido, (5) un grupo representado por la fórmula: -CO-R8 en donde RO es un grupo alquilo C1-6 opcionalmente sustituido o un grupo cíclico opcionalmente sustituido, o (6) un grupo representado por la fórmula: -O-R8' en donde R8' es un grupo alquilo C1-6 opcionalmente sustituido o un grupo cíclico opcionalmente sustituido, o una de sus sales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006317839 | 2006-11-24 | ||
JP2007232106 | 2007-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063912A1 true AR063912A1 (es) | 2009-02-25 |
Family
ID=39205144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105204A AR063912A1 (es) | 2006-11-24 | 2007-11-23 | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. |
Country Status (21)
Country | Link |
---|---|
US (2) | US20100056526A1 (es) |
EP (2) | EP2256115A1 (es) |
JP (1) | JP2010510962A (es) |
KR (1) | KR20090085117A (es) |
AR (1) | AR063912A1 (es) |
AU (1) | AU2007322608A1 (es) |
BR (1) | BRPI0719060A2 (es) |
CA (1) | CA2670404A1 (es) |
CL (1) | CL2007003352A1 (es) |
CO (1) | CO6231035A2 (es) |
CR (1) | CR10847A (es) |
EA (1) | EA200970510A1 (es) |
EC (1) | ECSP099461A (es) |
IL (1) | IL198819A0 (es) |
MA (1) | MA30985B1 (es) |
MX (1) | MX2009005449A (es) |
NO (1) | NO20092415L (es) |
PE (1) | PE20081228A1 (es) |
TN (1) | TN2009000199A1 (es) |
TW (1) | TW200829581A (es) |
WO (1) | WO2008062905A2 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7103906B1 (en) | 2000-09-29 | 2006-09-05 | International Business Machines Corporation | User controlled multi-device media-on-demand system |
MX336193B (es) | 2000-10-11 | 2016-01-11 | Rovi Guides Inc | Sistemas y metodos para proporcionar almacenamiento de datos en servidores, mediante un sistema de entrega de medios a peticion. |
US8086575B2 (en) | 2004-09-23 | 2011-12-27 | Rovi Solutions Corporation | Methods and apparatus for integrating disparate media formats in a networked media system |
US9681105B2 (en) | 2005-12-29 | 2017-06-13 | Rovi Guides, Inc. | Interactive media guidance system having multiple devices |
US8607287B2 (en) | 2005-12-29 | 2013-12-10 | United Video Properties, Inc. | Interactive media guidance system having multiple devices |
US7803940B2 (en) | 2006-11-24 | 2010-09-28 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases |
KR20090085117A (ko) * | 2006-11-24 | 2009-08-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로모노시클릭 화합물 및 이의 용도 |
US20090019492A1 (en) | 2007-07-11 | 2009-01-15 | United Video Properties, Inc. | Systems and methods for mirroring and transcoding media content |
ES2433225T3 (es) * | 2009-01-30 | 2013-12-10 | Takeda Pharmaceutical Company Limited | Compuesto con anillos condensados y uso del mismo |
JPWO2010095462A1 (ja) | 2009-02-23 | 2012-08-23 | 興和株式会社 | 新規な3−(5−アルコキシピリミジン−2−イル)ピリミジン−4(3h)−オン構造を有する化合物及びこれを含有する医薬 |
US8664226B2 (en) | 2009-04-17 | 2014-03-04 | Kowa Company, Ltd. | Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same |
EP2436675A1 (en) | 2009-05-29 | 2012-04-04 | Kowa Company, Ltd. | Novel -phenoxybenzeneacetic acid derivative and pharmaceutical preparation comprising same |
JPWO2011024468A1 (ja) | 2009-08-27 | 2013-01-24 | 興和株式会社 | 新規なスルホンアミド誘導体及びこれを含有する医薬 |
US9014546B2 (en) | 2009-09-23 | 2015-04-21 | Rovi Guides, Inc. | Systems and methods for automatically detecting users within detection regions of media devices |
TWI500611B (zh) * | 2009-09-29 | 2015-09-21 | Kowa Co | 新穎苯基吡啶衍生物及含有該衍生物之醫藥 |
WO2011077711A1 (ja) * | 2009-12-22 | 2011-06-30 | 興和株式会社 | 新規な2-ピリドン誘導体及びこれを含有する医薬 |
JPWO2011105099A1 (ja) * | 2010-02-25 | 2013-06-20 | 興和株式会社 | 新規な4−アルコキシピリミジン構造を有する化合物及びこれを含有する医薬 |
WO2011142381A1 (ja) * | 2010-05-11 | 2011-11-17 | Fujita Takashi | ベンゾ若しくはピリドイミダゾール誘導体 |
WO2012011592A1 (ja) * | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
UY33650A (es) | 2010-10-07 | 2012-04-30 | Takeda Pharmaceutical | Compuestos heterocíclicos |
WO2012078674A1 (en) | 2010-12-06 | 2012-06-14 | Confluence Life Sciences, Inc. | Substituted indole/indazole-pyrimidinyl compounds |
WO2012078673A1 (en) | 2010-12-06 | 2012-06-14 | Confluence Life Sciences, Inc. | Substituted pyridine urea compounds |
US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
EP2648516B1 (en) | 2010-12-06 | 2018-09-05 | Aclaris Therapeutics, Inc. | Substituted pyridinone-pyridinyl compounds |
PL2687523T3 (pl) * | 2011-03-14 | 2016-06-30 | Kowa Co | Nowa pochodna fenylopirydyny i lek zawierający ją |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013086208A1 (en) | 2011-12-06 | 2013-06-13 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
KR102011534B1 (ko) * | 2011-12-21 | 2019-08-16 | 오노 야꾸힝 고교 가부시키가이샤 | 인자 XIa 억제제로서 피리디논 및 피리미디논 유도체 |
JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
ES2869048T3 (es) | 2013-06-07 | 2021-10-22 | Aclaris Therapeutics Inc | Compuestos de piridinona-piridinilo sustituidos con metil/fluoro-piridinil-metoxi y compuestos de piridinona-piridinilo sustituidos con fluoro-pirimidinil-metoxi |
CN105473558B (zh) | 2013-06-20 | 2019-04-19 | 拜耳作物科学股份公司 | 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物 |
BR112015031155A2 (pt) | 2013-06-20 | 2017-07-25 | Bayer Cropscience Ag | derivados de sulfureto de arila e derivados de aril sulfóxido como acaricidas e inseticidas |
US9674563B2 (en) | 2013-11-04 | 2017-06-06 | Rovi Guides, Inc. | Systems and methods for recommending content |
RU2694254C1 (ru) | 2013-12-19 | 2019-07-11 | Саншайн Лейк Фарма Ко., Лтд. | Азотсодержащие гетероциклические производные и их применение в лекарственных препаратах |
EP3785714A1 (en) | 2014-04-01 | 2021-03-03 | Merck Sharp & Dohme Corp. | Prodrugs of hiv reverse transcriptase inhibitors |
PT3231803T (pt) | 2014-12-10 | 2020-09-03 | Ono Pharmaceutical Co | Derivado de di-hidroindolizinona |
US20190297887A1 (en) | 2016-07-12 | 2019-10-03 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pesticides |
KR101984121B1 (ko) * | 2017-08-21 | 2019-05-30 | 보령제약 주식회사 | 피리미디논 유도체 화합물 및 이의 용도 |
CN115666566A (zh) | 2020-03-27 | 2023-01-31 | 阿克拉瑞斯治疗股份有限公司 | 用于免疫病况的治疗的mk2途径抑制剂的口服组合物 |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411980A (en) * | 1989-07-28 | 1995-05-02 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
DE69013607T2 (de) | 1989-08-02 | 1995-03-02 | Takeda Chemical Industries Ltd | Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung. |
JPH03218371A (ja) | 1989-08-02 | 1991-09-25 | Takeda Chem Ind Ltd | ピラゾール誘導体 |
JP3032844B2 (ja) | 1990-02-15 | 2000-04-17 | 武田薬品工業株式会社 | ピリミジンジオン誘導体 |
DE69129998T2 (de) | 1990-02-15 | 1998-12-24 | Takeda Chemical Industries Ltd | Pyrimidindionderivate, deren Herstellung und Verwendung |
JP3114073B2 (ja) | 1990-03-07 | 2000-12-04 | 武田薬品工業株式会社 | アンジオテンシンii拮抗薬−含窒素異項環化合物 |
CA2037630C (en) * | 1990-03-07 | 2001-07-03 | Akira Morimoto | Nitrogen-containing heterocylic compounds, their production and use |
US5166206A (en) * | 1990-03-30 | 1992-11-24 | Merck & Co., Inc. | Substituted pyrimidines, pyrimidinones and pyridopyrimidines |
US5472967A (en) * | 1991-02-20 | 1995-12-05 | Synthelabo | 4-pyrimidinone derivatives their preparation and their application in therapy |
IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
IT1250749B (it) * | 1991-08-02 | 1995-04-21 | Luso Farmaco Inst | Composti eterociclici ad attivita' a ii antagonista |
EP0829479B1 (en) | 1992-09-14 | 2004-04-14 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds and their use as angiotensin II antagonists |
JPH06239859A (ja) | 1992-09-14 | 1994-08-30 | Takeda Chem Ind Ltd | アンギオテンシンii拮抗作用を有する環状化合物およびその用途 |
ATE204276T1 (de) | 1992-12-22 | 2001-09-15 | Takeda Chemical Industries Ltd | Heterocyclische verbindungen mit angiotensin-ii- antagonistischer wirkung und ihre anwendung |
JP3412887B2 (ja) | 1992-12-22 | 2003-06-03 | 武田薬品工業株式会社 | アンギオテンシンii拮抗作用を有する複素環化合物およびその用途 |
US20010020100A1 (en) * | 1994-06-14 | 2001-09-06 | G.D. Searle & Co. | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders |
US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
AU1285499A (en) | 1997-10-30 | 1999-05-24 | Merck & Co., Inc. | Somatostatin agonists |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
EP1227090A4 (en) | 1999-10-07 | 2002-11-20 | Tadeka Chemical Ind Ltd | AMIN DERIVATIVES |
ES2225252T3 (es) | 1999-11-10 | 2005-03-16 | Takeda Chemical Industries, Ltd. | Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica. |
CA2407149C (en) | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
US6974806B2 (en) | 2000-07-13 | 2005-12-13 | Takeda Pharmaceutical Company Limited | Lipid-rich plaque inhibitors |
WO2003042204A1 (fr) | 2001-10-19 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Derive d'amine |
PL371319A1 (en) | 2002-01-11 | 2005-06-13 | Takeda Pharmaceutical Company Limited | Coumarin derivatives, process for their production and use thereof |
WO2004048363A1 (ja) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | イミダゾール誘導体、その製造法および用途 |
KR20090085117A (ko) * | 2006-11-24 | 2009-08-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로모노시클릭 화합물 및 이의 용도 |
US7803940B2 (en) * | 2006-11-24 | 2010-09-28 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases |
-
2007
- 2007-11-21 KR KR1020097012959A patent/KR20090085117A/ko not_active Application Discontinuation
- 2007-11-21 MX MX2009005449A patent/MX2009005449A/es not_active Application Discontinuation
- 2007-11-21 JP JP2009521472A patent/JP2010510962A/ja not_active Abandoned
- 2007-11-21 EP EP10173592A patent/EP2256115A1/en not_active Withdrawn
- 2007-11-21 US US12/516,099 patent/US20100056526A1/en not_active Abandoned
- 2007-11-21 US US11/943,910 patent/US20080207654A1/en not_active Abandoned
- 2007-11-21 WO PCT/JP2007/073004 patent/WO2008062905A2/en active Application Filing
- 2007-11-21 EA EA200970510A patent/EA200970510A1/ru unknown
- 2007-11-21 BR BRPI0719060-3A2A patent/BRPI0719060A2/pt not_active IP Right Cessation
- 2007-11-21 EP EP07832719A patent/EP2074117A2/en not_active Withdrawn
- 2007-11-21 CA CA002670404A patent/CA2670404A1/en not_active Abandoned
- 2007-11-21 AU AU2007322608A patent/AU2007322608A1/en not_active Abandoned
- 2007-11-23 CL CL200703352A patent/CL2007003352A1/es unknown
- 2007-11-23 AR ARP070105204A patent/AR063912A1/es not_active Application Discontinuation
- 2007-11-23 TW TW096144409A patent/TW200829581A/zh unknown
- 2007-11-23 PE PE2007001629A patent/PE20081228A1/es not_active Application Discontinuation
-
2009
- 2009-05-19 IL IL198819A patent/IL198819A0/en unknown
- 2009-05-20 TN TNP2009000199A patent/TN2009000199A1/fr unknown
- 2009-06-09 CR CR10847A patent/CR10847A/es unknown
- 2009-06-10 MA MA31977A patent/MA30985B1/fr unknown
- 2009-06-23 EC EC2009009461A patent/ECSP099461A/es unknown
- 2009-06-24 CO CO09065607A patent/CO6231035A2/es not_active Application Discontinuation
- 2009-06-24 NO NO20092415A patent/NO20092415L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2009005449A (es) | 2009-06-02 |
NO20092415L (no) | 2009-08-17 |
ECSP099461A (es) | 2009-11-30 |
CO6231035A2 (es) | 2010-12-20 |
PE20081228A1 (es) | 2008-10-29 |
WO2008062905A3 (en) | 2008-12-04 |
EP2256115A1 (en) | 2010-12-01 |
AU2007322608A1 (en) | 2008-05-29 |
US20100056526A1 (en) | 2010-03-04 |
JP2010510962A (ja) | 2010-04-08 |
EP2074117A2 (en) | 2009-07-01 |
CR10847A (es) | 2009-07-13 |
AU2007322608A2 (en) | 2009-07-16 |
KR20090085117A (ko) | 2009-08-06 |
MA30985B1 (fr) | 2009-12-01 |
WO2008062905A2 (en) | 2008-05-29 |
US20080207654A1 (en) | 2008-08-28 |
TN2009000199A1 (en) | 2010-10-18 |
CA2670404A1 (en) | 2008-05-29 |
CL2007003352A1 (es) | 2008-07-04 |
TW200829581A (en) | 2008-07-16 |
BRPI0719060A2 (pt) | 2014-02-04 |
EA200970510A1 (ru) | 2009-12-30 |
IL198819A0 (en) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
AR071531A1 (es) | Compuesto cristalino heteromonociclico | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR082499A1 (es) | Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos | |
AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
UY33458A (es) | Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos | |
AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
AR070469A1 (es) | Derivados de naftiridina y composiciones farmaceuticas como inhibidores de quinasa con actividad sobre c- kit y pdgfr | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
ES2640911T3 (es) | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus | |
AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
AR069509A1 (es) | Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10 | |
SV2009003199A (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
ECSP088257A (es) | Derivados de amida | |
AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |